Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Denosumab for bone erosions in gout
NCT02903446Phase 2Completed
- Sponsor
- University of Alabama at Birmingham
- Start
- Feb 2017
- Primary completion
- Mar 2020
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of denosumab in gout (2 arms), sponsored by University of Alabama at Birmingham. Primary endpoint: CT Bone Erosion Score at 12 months. Started Feb 2017; status: completed.
02
Drugs
denosumab
03
Conditions
gout
Beyond the preview
Go deeper on NCT02903446.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02903446.